The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Year to date metric has recorded a loss of -7.54%.However, over the last six months, we can see a stronger performance of -9.53%. Over the last 30 days, the price of NBIX has leaped by -13.71%. And in the last five days, it has fallen by -19.26%.
In terms of market performance, Neurocrine Biosciences, Inc. had a fairly even. The highest value for the stock in the past year was $157.98 on 08/01/24, and the lowest value was recorded at $103.63 on 11/10/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of NBIX Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Neurocrine Biosciences, Inc.’s current trading price is -22.88% away from its 52-week high, while its distance from the 52-week low is 17.56%. The stock’s price range during this time has been between $103.63 and $157.98. The trading volume for the Healthcare sector company’s shares reached about 2.79 million for the day, which was higher than the average daily volume of 0.79 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Neurocrine Biosciences, Inc. (NBIX) has experienced a quarterly decline of -9.50% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 12.30B and boasts a workforce of 1400 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 140.72, with a change in price of -16.04. Similarly, Neurocrine Biosciences, Inc. recorded 790,130 in trading volume during the last 100 days, posting a change of -11.55%.
NBIX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NBIX stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.10.
NBIX Stock Stochastic Average
Today, Neurocrine Biosciences, Inc.’s raw stochastic average for the past 50 days stands at 8.15%, indicating a rise from the raw stochastic average of the last 20 days, which was 8.15%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 50.69% and 65.32% respectively.
